Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)
Status:
Completed
Trial end date:
2018-08-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether ThermoDox, a thermally sensitive liposomal
doxorubicin, is effective in the treatment of non-resectable hepatocellular carcinoma when
used in conjunction with standardized radiofrequency ablation (sRFA).